Improving Therapeutic Odyssey

Preemptive Pharmacogenomics Utility in Patient Care

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Pharmacogenomics, studying genetic variation related to drug response, was established decades ago. Today, performing clinical pharmacogenomics testing has increased, creating great potential to improve patient care. Yet widespread implementation of pharmacogenomics in practice is currently limited, resulting in the “therapeutic odyssey” of patients. Preemptive clinical pharmacogenomics testing prior to the time of prescribing is now emerging as an option that could tailor the pharmacotherapy of patients by increasing drug effectiveness while reducing adverse drug reaction risk.

Original languageEnglish (US)
Pages (from-to)39-41
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume101
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pharmacogenetics
Patient Care
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Drug Therapy
Therapeutics
Pharmacogenomic Testing

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Improving Therapeutic Odyssey : Preemptive Pharmacogenomics Utility in Patient Care. / Lazaridis, Konstantinos N.

In: Clinical Pharmacology and Therapeutics, Vol. 101, No. 1, 01.01.2017, p. 39-41.

Research output: Contribution to journalArticle

@article{46d30228671744809dfad2eda518fb6d,
title = "Improving Therapeutic Odyssey: Preemptive Pharmacogenomics Utility in Patient Care",
abstract = "Pharmacogenomics, studying genetic variation related to drug response, was established decades ago. Today, performing clinical pharmacogenomics testing has increased, creating great potential to improve patient care. Yet widespread implementation of pharmacogenomics in practice is currently limited, resulting in the “therapeutic odyssey” of patients. Preemptive clinical pharmacogenomics testing prior to the time of prescribing is now emerging as an option that could tailor the pharmacotherapy of patients by increasing drug effectiveness while reducing adverse drug reaction risk.",
author = "Lazaridis, {Konstantinos N}",
year = "2017",
month = "1",
day = "1",
doi = "10.1002/cpt.543",
language = "English (US)",
volume = "101",
pages = "39--41",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Improving Therapeutic Odyssey

T2 - Preemptive Pharmacogenomics Utility in Patient Care

AU - Lazaridis, Konstantinos N

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Pharmacogenomics, studying genetic variation related to drug response, was established decades ago. Today, performing clinical pharmacogenomics testing has increased, creating great potential to improve patient care. Yet widespread implementation of pharmacogenomics in practice is currently limited, resulting in the “therapeutic odyssey” of patients. Preemptive clinical pharmacogenomics testing prior to the time of prescribing is now emerging as an option that could tailor the pharmacotherapy of patients by increasing drug effectiveness while reducing adverse drug reaction risk.

AB - Pharmacogenomics, studying genetic variation related to drug response, was established decades ago. Today, performing clinical pharmacogenomics testing has increased, creating great potential to improve patient care. Yet widespread implementation of pharmacogenomics in practice is currently limited, resulting in the “therapeutic odyssey” of patients. Preemptive clinical pharmacogenomics testing prior to the time of prescribing is now emerging as an option that could tailor the pharmacotherapy of patients by increasing drug effectiveness while reducing adverse drug reaction risk.

UR - http://www.scopus.com/inward/record.url?scp=85006110978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006110978&partnerID=8YFLogxK

U2 - 10.1002/cpt.543

DO - 10.1002/cpt.543

M3 - Article

VL - 101

SP - 39

EP - 41

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -